XBI 250103 87.50P (XBI250103P87500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

XBI250103P87500

Watchlist

0.05
-0.13-72.22%

15min DelayClose Jan 2 16:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
MT NewswiresDec 27, 2024 15:49 ET
SPDR S&P Biotech ETF Declares Quarterly Distribution of $0.0027
Seeking AlphaDec 23, 2024 07:14 ET
SPDR S&P Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 0.00269 USD Dividend Per Share
Moomoo NewsDec 20, 2024 19:40 ET
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
WSJDec 20, 2024 15:11 ET
20 ETFs Primed For Unusually Big Swings On Fed Meeting Days
BenzingaDec 18, 2024 10:40 ET
Express News | Live On CNBC, Joe Terranova Announces Sold SPDR Series Trust SPDR S&P Biotech ETF
BenzingaDec 16, 2024 12:23 ET

Comments

topcing

Nov 4, 2024 21:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25, 2024 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 11, 2024 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6, 2024 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25, 2024 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?